GIP receptor blocker: research tool for studying tirzepatide's gut hormone target (GIP 6-30 amide)
A lab-made fragment of the gut hormone GIP that blocks the GIP receptor without switching it on, used only as a lab research tool to study how tirzepatide works.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
GIP(6-30)amide is a shortened, synthetic version of a gut hormone called GIP (gastric inhibitory polypeptide, also known as glucose-dependent insulinotropic polypeptide). The full-length GIP is 42 amino acids long and is released from the small intestine after eating; it helps stimulate insulin secretion and plays a role in fat storage and energy balance (Seino and colleagues 2010, Bailey and colleagues 2024). GIP(6-30)amide covers only residues 6 through 30 of that parent sequence and carries a C-terminal amide modification not represented in the stored 25-residue raw sequence. By trimming the first five residues — which are required to switch the GIP receptor on — this fragment retains binding ability but loses the ability to activate the receptor, making it a competitive antagonist at the GIP receptor (GIPR). It is used as a pharmacological research tool rather than as a therapeutic agent in its own right.
History
GIP itself has a long scientific history. It was originally identified in the 1960s–1970s as "enterogastrone," a factor from the intestine that inhibited gastric acid secretion, before being recognized as a major metabolic incretin hormone over subsequent decades (Marks 2020). By the early 1990s, the GIP receptor had been cloned and shown to be a member of the secretin/vasoactive intestinal peptide receptor family — now classified as class B G-protein-coupled receptors (GPCRs) — distributed widely in peripheral organs and in the brain (Usdin and colleagues 1993). Truncated GIP fragments lacking the N-terminal activation motif emerged as antagonist tools during efforts to probe GIPR physiology, predating and then paralleling the intense interest in GIPR as a drug target that arose with the development of dual GLP-1R/GIPR agonists.
What it does
GIP(6-30)amide blocks the GIP receptor without activating it. Under experimental conditions, it competes with native GIP for receptor binding, dampening or abolishing GIP-driven insulin secretion and the downstream metabolic effects that GIP normally produces. Because tirzepatide — an approved dual agonist of both GLP-1R and GIPR — relies on GIPR agonism for part of its metabolic effect, antagonists like GIP(6-30)amide give researchers a way to isolate the GIPR contribution and test what happens when only one receptor arm is active (Novikoff and colleagues 2021; Anastasiou and colleagues 2025). The receptor antagonism debate has also grown more nuanced: while tirzepatide takes the agonist-at-GIPR route, a separate strategy couples a GIPR antagonist directly with GLP-1 agonist activity — as seen in AMG 133 (maridebart cafraglutide), which showed weight-loss effects in preclinical and Phase 1 settings (Véniant and colleagues 2024).
Evidence
- Human: GIP(6-30)amide is a research-grade antagonist tool used in human-cell assay and ex vivo systems to characterize GIPR pharmacology; no therapeutic clinical trials have been conducted with this fragment.
- Animal: Truncated GIP antagonist fragments, including C-terminally amidated variants, have been used in rodent models to examine the role of endogenous GIP in insulin secretion and metabolic regulation (Drucker 2003).
- In vitro: The fragment class underlies receptor pharmacology studies comparing GIPR agonists and antagonists across species; species differences in how structurally related antagonists behave at rodent vs. human GIPR have been documented, motivating use of human-sequence GIP(6-30)amide specifically when human GIPR biology is the target (Sparre-Ulrich and colleagues 2016).
Known effects
- GIPR blockade — Competitive antagonist at human GIPR; inhibits GIP-stimulated insulin secretion in receptor assays (Mechanistic / in vitro)
- Research probe for incretin biology — Used to dissect relative contributions of GIP vs. GLP-1 signaling in dual-agonist pharmacology contexts (Mechanistic)
- No established metabolic effect in intact humans — Not evaluated as a stand-alone therapeutic; physiological effects in humans are inferred from receptor studies
Mechanism
GIPR belongs to the class B family of GPCRs — the same family as the GLP-1 receptor, glucagon receptor, and PTH receptor (Usdin and colleagues 1993; Seino and colleagues 2010). Full-length GIP activates GIPR through an N-terminal binding-and-activation mechanism common to class B ligands: the C-terminal portion of the ligand docks in the extracellular domain of the receptor, and the N-terminal segment inserts into the transmembrane bundle to trigger Gαs-mediated cAMP elevation in target cells such as pancreatic β-cells. GIP(6-30)amide retains the C-terminal receptor-docking region (residues 6–30) but lacks the N-terminal activation segment (residues 1–5). The result is competitive occupancy without activation — classical competitive antagonism. The C-terminal amide group (replacing the free carboxyl that would be present in a natural proteolytic fragment) helps stabilize the peptide against carboxypeptidase degradation, extending its useful lifetime in assay systems. The human-sequence fragment is particularly valuable because GIPR antagonist pharmacology shows meaningful species differences: (Pro3)GIP, for example, behaves as a full agonist at human GIPR but as only a partial agonist or competitive antagonist at rodent GIPR, meaning rodent-derived data may not translate directly (Sparre-Ulrich and colleagues 2016).
Related peptides
- Full-length GIP and its receptor define the system that GIP(6-30)amide is designed to probe; see also the tirzepatide card for the dual GLP-1R/GIPR agonist that has made GIPR pharmacology clinically prominent.
- The duodenal enteroendocrine cell biology that releases GIP into circulation is discussed alongside GLP-1 in the incretin literature (Bailey and colleagues 2024; Drucker 2003).
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Does this peptide gain a defined structure only after it grabs onto the GIP receptor?
If true, it would explain why tiny changes at one end of the peptide flip it from activator to blocker. That knowledge could help chemists design cleaner, more potent GIP receptor blockers for obesity and diabetes research.
Can this peptide block GIP's fat-storage signals in fat cells separately from its blood sugar effects?
If yes, researchers could use it to figure out exactly why tirzepatide-type dual drugs cause more weight loss than older diabetes drugs. That insight could point to new obesity treatments targeting fat tissue directly.
Does the chemical modification at the very end of GIP(6-30)amide explain most of its ability to block the GIP receptor?
If a single chemical group controls the switch between blocking and activating, drug designers could tune that end of the peptide to create better tools for studying diabetes and obesity, or even new medicines.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.7566775679588318 | openfold3-mlx |
| ranking score | 0.8189804553985596 | openfold3-mlx |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 0.777 | global PDE — lower = better |
| disorder | 0.155 | fraction disordered |
| chain pair ipTM (A, B) | 0.757 | interface quality |
▸3-letter notation
▸recipeopenfold3-mlx 0.3.1
| parameter | value |
|---|---|
| model | openfold3-mlx 0.3.1 |
| weights | aedd8f3eb814e392… |
| hardware | apple_m4_base_16gb |
| mlx version | 0.31.1 |
| python | 3.14.3 |
| random seed | 42 |
| msa strategy | colabfold |
| diffusion samples | 1 |
| runtime | 421s |
| predicted by | mlx@peptide |
| predicted at | 2026-04-22 |
python3 openfold3/run_openfold.py predict --query_json {query.json} --runner_yaml examples/example_runner_yamls/mlx_runner.yml --output_dir {output_dir} --num_diffusion_samples 1 ▸citationbibtex
@peptide{pep10537,
sequence = {FISDYSIAMDKIHQQDFVNWLLAQK},
target = {gipr},
author = {peptidemodel},
year = {2026},
status = {synthesized}
}